Your browser doesn't support javascript.
Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies.
Peluso, Michael J; Anglin, Khamal; Durstenfeld, Matthew S; Martin, Jeffrey N; Kelly, J Daniel; Hsue, Priscilla Y; Henrich, Timothy J; Deeks, Steven G.
  • Peluso MJ; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA.
  • Anglin K; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA.
  • Durstenfeld MS; Division of Cardiology, University of California, San Francisco, San Francisco, CA.
  • Martin JN; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA.
  • Kelly JD; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA.
  • Hsue PY; Division of Cardiology, University of California, San Francisco, San Francisco, CA.
  • Henrich TJ; Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA.
  • Deeks SG; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA.
Pathog Immun ; 7(1): 95-103, 2022.
Article in English | MEDLINE | ID: covidwho-1924851
ABSTRACT

Background:

Efforts to understand the impact of SARS-CoV-2 variants, vaccine status, and treatment on the development and persistence of Long COVID have intensified.

Methods:

We report 4 sequential cases from a post-COVID cohort study demonstrating variability in outcomes following differentially timed nirmatrelvir therapy, received as part of clinical care.

Results:

In the first case, the participant experienced symptomatic rebound and developed Long COVID despite early initiation of antiviral therapy. In the next 2 cases, participants reported improvement in persistent COVID symptoms when nirmatrelvir was taken 25 and 60 days following initial symptom onset. In the final case, an individual with presumed Long COVID for 2 years reported substantial improvement in chronic symptoms when taking nirmatrelvir following SARS-CoV-2 re-infection.

Conclusions:

These anecdotes suggest that systematic study of antiviral therapy for Long COVID is warranted.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Systematic review/Meta Analysis Topics: Long Covid / Vaccines / Variants Language: English Journal: Pathog Immun Year: 2022 Document Type: Article Affiliation country: Pai.v7i1.518

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Systematic review/Meta Analysis Topics: Long Covid / Vaccines / Variants Language: English Journal: Pathog Immun Year: 2022 Document Type: Article Affiliation country: Pai.v7i1.518